Literature DB >> 28320852

Reprogramming Innate Immune Signaling in Cardiometabolic Disease.

Yaxing Zhang1, Xiao-Jing Zhang1, Pi-Xiao Wang1, Peng Zhang1, Hongliang Li2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28320852     DOI： 10.1161/HYPERTENSIONAHA.116.08192

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  3 in total

1.  Carboxyl-Terminal Modulator Protein Ameliorates Pathological Cardiac Hypertrophy by Suppressing the Protein Kinase B Signaling Pathway.

Authors:  Xiaoxiong Liu; Qin Yang; Li-Hua Zhu; Jia Liu; Ke-Qiong Deng; Xue-Yong Zhu; Ye Liu; Jun Gong; Peng Zhang; Shuyan Li; Hao Xia; Zhi-Gang She
Journal:  J Am Heart Assoc       Date:  2018-06-26       Impact factor: 5.501

2.  H2 Protects Against Lipopolysaccharide-Induced Cardiac Dysfunction via Blocking TLR4-Mediated Cytokines Expression.

Authors:  Sihua Tan; Zhiyuan Long; Xiangping Hou; Yujie Lin; Jingting Xu; Xinchao You; Tinghuai Wang; Yaxing Zhang
Journal:  Front Pharmacol       Date:  2019-08-05       Impact factor: 5.810

Review 3.  Noble Gases Therapy in Cardiocerebrovascular Diseases: The Novel Stars?

Authors:  Jiongshan Zhang; Wei Liu; Mingmin Bi; Jinwen Xu; Hongzhi Yang; Yaxing Zhang
Journal:  Front Cardiovasc Med       Date:  2022-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.